Intermediate-risk Prostate Cancer: Stratification and Management

D’Amico, 1998, Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer, JAMA, 280, 969, 10.1001/jama.280.11.969 Mottet, 2019 Mohler, 2019, Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology, J Natl Compr Canc Netw, 17, 479, 10.6004/jnccn.2019.0023 Sanda Martin, 2018, Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. Part I: risk stratification, shared decision making, and care options, J Urol, 199, 683, 10.1016/j.juro.2017.11.095 Zumsteg, 2013, A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy, Eur Urol, 64, 895, 10.1016/j.eururo.2013.03.033 Keane, 2015, Androgen deprivation therapy and the risk of death from prostate cancer among men with favorable or unfavorable intermediate-risk disease, Cancer, 121, 2713, 10.1002/cncr.29420 Zumsteg, 2017, Number of unfavorable intermediate-risk factors predicts pathologic upstaging and prostate cancer-specific mortality following radical prostatectomy: results from the SEARCH database, Prostate, 77, 154, 10.1002/pros.23255 Draulans, 2019, Impact of magnetic resonance imaging on prostate cancer staging and European Association of Urology risk classification, Urology, 130, 113, 10.1016/j.urology.2019.04.023 Bass, 2019, Targeted biopsy of the prostate: does this result in improvement in detection of high-grade cancer or the occurrence of the Will Rogers phenomenon?, BJU Int, 124, 643, 10.1111/bju.14806 Hamdy, 2016, 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer, N Engl J Med, 375, 1415, 10.1056/NEJMoa1606220 Wilt, 2017, Follow-up of prostatectomy versus observation for early prostate cancer, N Engl J Med, 377, 132, 10.1056/NEJMoa1615869 Bill-Axelson, 2018, Radical prostatectomy or watchful waiting in prostate cancer—29-year follow-up, N Engl J Med, 379, 2319, 10.1056/NEJMoa1807801 Klotz, 2015, Long-term follow-up of a large active surveillance cohort of patients with prostate cancer, J Clin Oncol, 33, 272, 10.1200/JCO.2014.55.1192 Masic, 2018, Effects of initial Gleason grade on outcomes during active surveillance for prostate cancer, Eur Urol Oncol, 1, 386, 10.1016/j.euo.2018.04.018 Kornberg, 2019, Genomic prostate score, PI-RADSTM version 2 and progression in men with prostate cancer on active surveillance, J Urol, 201, 300, 10.1016/j.juro.2018.08.047 Falagario, 2019, Defining prostate cancer at favorable intermediate risk: the potential utility of magnetic resonance imaging and genomic tests, J Urol, 202, 102, 10.1097/JU.0000000000000134 Herlemann, 2020, Decipher identifies men with otherwise clinically favorable-intermediate risk disease who may not be good candidates for active surveillance, Prostate Cancer Prostatic Dis, 23, 136, 10.1038/s41391-019-0167-9 Noguchi, 2003, Prognostic factors for multifocal prostate cancer in radical prostatectomy specimens: lack of significance of secondary cancers, J Urol, 170, 459, 10.1097/01.ju.0000070928.49986.04 Blazevski A., Scheltema M.J., Yuen B., et al. Oncological and quality-of-life outcomes following focal irreversible electroporation as primary treatment for localised prostate cancer: a biopsy-monitored prospective cohort. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2019.04.008. Shah, 2019, Early-medium-term outcomes of primary focal cryotherapy to treat nonmetastatic clinically significant prostate cancer from a prospective multicentre registry, Eur Urol, 76, 98, 10.1016/j.eururo.2018.12.030 Rischmann, 2017, Focal high intensity focused ultrasound of unilateral localized prostate cancer: a prospective multicentric hemiablation study of 111 patients, Eur Urol, 71, 267, 10.1016/j.eururo.2016.09.039 Feijoo, 2016, Focal high-intensity focused ultrasound targeted hemiablation for unilateral prostate cancer: a prospective evaluation of oncologic and functional outcomes, Eur Urol, 69, 214, 10.1016/j.eururo.2015.06.018 Ganzer, 2018, Prospective multicenter phase II study on focal therapy (hemiablation) of the prostate with high intensity focused ultrasound, J Urol, 199, 983, 10.1016/j.juro.2017.10.033 Guillaumier, 2018, A multicentre study of 5-year outcomes following focal therapy in treating clinically significant nonmetastatic prostate cancer, Eur Urol, 74, 422, 10.1016/j.eururo.2018.06.006 Albisinni, 2017, Comparing high-intensity focal ultrasound hemiablation to robotic radical prostatectomy in the management of unilateral prostate cancer: a matched-pair analysis, J Endourol, 31, 14, 10.1089/end.2016.0702 Kurbegovic, 2017, The risk of biochemical recurrence for intermediate-risk prostate cancer after radical prostatectomy, Scand J Urol, 51, 450, 10.1080/21681805.2017.1356369 Beauval, 2017, Improved decision making in intermediate-risk prostate cancer: a multicenter study on pathologic and oncologic outcomes after radical prostatectomy, World J Urol, 35, 1191, 10.1007/s00345-016-1979-z Wallis, 2016, Surgery versus radiotherapy for clinically-localized prostate cancer: a systematic review and meta-analysis, Eur Urol, 70, 21, 10.1016/j.eururo.2015.11.010 Soni, 2019, Comparison of population-based observational studies with randomized trials in oncology, J Clin Oncol, 37, 1209, 10.1200/JCO.18.01074 Roach, 2015, Radical prostatectomy versus radiation and androgen deprivation therapy for clinically localized prostate cancer: how good is the evidence?, Int J Radiat Oncol Biol Phys, 93, 1064, 10.1016/j.ijrobp.2015.08.005 Robinson, 2018, Prostate cancer death after radiotherapy or radical prostatectomy: a nationwide population-based observational study, Eur Urol, 73, 502, 10.1016/j.eururo.2017.11.039 Giberti, 2017, Robotic prostatectomy versus brachytherapy for the treatment of low risk prostate cancer, Can J Urol, 24, 8728 Frank, 2018, Prospective phase 2 trial of permanent seed implantation prostate brachytherapy for intermediate-risk localized prostate cancer: efficacy, toxicity, and quality of life outcomes, Int J Radiat Oncol, 100, 374, 10.1016/j.ijrobp.2017.09.050 Prestidge, 2016, Initial report of NRG oncology/RTOG 0232: a phase 3 study comparing combined external beam radiation and transperineal interstitial permanent brachytherapy with brachytherapy alone for selected patients with intermediate-risk prostatic carcinoma, Int J Radiat Oncol Biol Phys, 96, S4, 10.1016/j.ijrobp.2016.06.026 Morris, 2017, Int J Radiat Oncol Biol Phys, 98, 275, 10.1016/j.ijrobp.2016.11.026 D’Amico, 2004, 6-Month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial, JAMA, 292, 821, 10.1001/jama.292.7.821 D’Amico, 2008, Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial, JAMA, 299, 289, 10.1001/jama.299.3.289 Jones, 2011, Radiotherapy and short-term androgen deprivation for localized prostate cancer, N Engl J Med, 365, 107, 10.1056/NEJMoa1012348 Denham, 2011, Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial, Lancet Oncol, 12, 451, 10.1016/S1470-2045(11)70063-8 Zapatero, 2015, High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial, Lancet Oncol, 16, 320, 10.1016/S1470-2045(15)70045-8 Bolla, 2016, Short androgen suppression and radiation dose escalation for intermediate- and high-risk localized prostate cancer: results of EORTC trial 22991, J Clin Oncol, 34, 1748, 10.1200/JCO.2015.64.8055 Keane, 2014, The likelihood of death from prostate cancer in men with favorable or unfavorable intermediate-risk disease, Cancer, 120, 1787, 10.1002/cncr.28609 Dubray, 2016, Does short-term androgen depletion add to high dose radiotherapy (80 Gy) in localized intermediate risk prostate cancer? Final analysis of GETUG 14 randomized trial (EU-20503/NCT00104741), J Clin Oncol, 34, 5021, 10.1200/JCO.2016.34.15_suppl.5021 Kuban, 2008, Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer, Int J Radiat Oncol Biol Phys, 70, 67, 10.1016/j.ijrobp.2007.06.054 Beckendorf, 2011, 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial, Int J Radiat Oncol Biol Phys, 80, 1056, 10.1016/j.ijrobp.2010.03.049 Creak, 2013, Randomised pilot study of dose escalation using conformal radiotherapy in prostate cancer: long-term follow-up, Br J Cancer, 109, 651, 10.1038/bjc.2013.394 Dearnaley, 2014, Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial, Lancet Oncol, 15, 464, 10.1016/S1470-2045(14)70040-3 Heemsbergen, 2014, Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival, Radiother Oncol, 110, 104, 10.1016/j.radonc.2013.09.026 Michalski, 2018, Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer: the NRG oncology RTOG 0126 randomized clinical trial, JAMA Oncol, 4, e180039, 10.1001/jamaoncol.2018.0039 Lee, 2016, Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer, J Clin Oncol, 34, 2325, 10.1200/JCO.2016.67.0448 Dearnaley, 2016, Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial, Lancet Oncol, 17, 1047, 10.1016/S1470-2045(16)30102-4 Catton, 2017, Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer, J Clin Oncol, 35, 1884, 10.1200/JCO.2016.71.7397 Incrocci, 2016, Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial, Lancet Oncol, 17, 1061, 10.1016/S1470-2045(16)30070-5 Hoffman, 2018, Randomized trial of hypofractionated, dose-escalated, intensity-modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer, J Clin Oncol, 36, 2943, 10.1200/JCO.2018.77.9868 Widmark, 2019, Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial, Lancet, 394, 385, 10.1016/S0140-6736(19)31131-6 Fuller, 2018, Phase 2 multicenter trial of heterogeneous-dosing stereotactic body radiotherapy for low- and intermediate-risk prostate cancer: 5-year outcomes, Eur Urol Oncol, 1, 540, 10.1016/j.euo.2018.06.013 Kishan, 2019, Long-term outcomes of stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer, JAMA Netw Open, 2, e188006, 10.1001/jamanetworkopen.2018.8006 Castro, 2013, Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer, J Clin Oncol, 31, 1748, 10.1200/JCO.2012.43.1882 Na, 2017, Germline mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death, Eur Urol, 71, 740, 10.1016/j.eururo.2016.11.033